Sees Q1 revenues $370M-$376M, consensus $397.95M. Q1 revenue view represents a growth of approximately (1.5%) to flat and organic growth of approximately 2.0% to 3.5%. Organic sales growth excludes acquisitions and divestitures as well as the effects of foreign currency and the year- over-year change in revenue from discontinued products.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
- Integra LifeSciences to Host Fourth Quarter 2022 Financial Results Conference Call on February 22, 2023
- Piper Sandler maintains cautious stance on Integra LifeSciences
- Integra LifeSciences sees Q4 EPS 92c-96c, consensus 89c
- Integra LifeSciences confirms Carrie Anderson to step down as CFO
